News | April 27, 2023
Biocon approves NCD issue
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The business and product range of Ipca and that of Unichem complements each others business and product range
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
A special technique of jet injection is used to make vaccination almost painless and totally needleless.
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Subscribe To Our Newsletter & Stay Updated
